Eli Lilly and Company (LLY) is a leading drug manufacturers-general business based in the US. In the week up to 13 September Eli Lilly and Company shares plunged 8.52% to a closing position of $233.09. However, over the last 12 months, Eli Lilly and Company's share price has risen by 49.25% from $154.17. Eli Lilly and Company is listed on the NYSE and employs 34,657 staff. All prices are listed in US Dollars.
Best for
US shares
Best for
Low-cost
Best for
Beginners
Best for
Range of stock exchanges
Since the stock market crash that started in February 2020, Eli Lilly and Company's share price has had significant positive movement.
Its last market close was $230.1, which is 38.27% up on its pre-crash value of $142.04 and 96.57% up on the lowest point reached during the March 2020 crash when the shares fell as low as $117.06.
If you had bought $1,000 worth of Eli Lilly and Company shares at the start of February 2020, those shares would have been worth $844.06 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,631.41.
| Open | $229.71 |
|---|---|
| High | $230.83 |
| Low | $228.23 |
| Close | $230.1 |
| Previous close | $231.04 |
| Change | $-0.94 |
| Change % | -0.4069% |
| Volume | 4,480,241 |
| 52-week range | $127.0495 - $275.87 |
|---|---|
| 50-day moving average | $257.4897 |
| 200-day moving average | $218.8097 |
| Wall St. target price | $262.24 |
| PE ratio | 34.6015 |
| Dividend yield | $3.18 (1.38%) |
| Earnings per share (TTM) | $6.65 |
Other fees apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | No minimum | £3.79 £845.03 total |
Capital at risk |
|
£0 | $50 | £4.21 £845.45 total |
Capital at risk |
 |
£0 | £0.01 | £1.28 £842.53 total |
Capital at risk |
 |
£0 | £50 | £4.22 £845.47 total |
Capital at risk |
|
£0 | £1 | £20.38 £861.62 total |
Capital at risk |
 |
£9.99 per month | No minimum | £20.62 £861.87 total |
Capital at risk |
 |
£0 | No minimum | £8.41 £849.66 total |
Capital at risk |
 |
£36 per year | £20 | £20.03 £861.28 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $230.1
| 1 week (2021-09-13) | -3.30% |
|---|---|
| 1 month (2021-08-20) | -15.06% |
| 3 months (2021-06-18) | 5.28% |
| 6 months (2021-03-19) | 24.86% |
| 1 year (2020-09-18) | 49.25% |
|---|---|
| 2 years (2019-09-20) | 98.09% |
| 3 years (2018-09-20) | 116.93% |
| 5 years (2016-09-20) | 188.06% |
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Eli Lilly and Company shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6341. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $9.1 billion (£6.6 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $26.7 billion |
|---|---|
| Operating margin TTM | 28.52% |
| Gross profit TTM | $19.1 billion |
| Return on assets TTM | 10.61% |
| Return on equity TTM | 111.03% |
| Profit margin | 22.71% |
| Book value | $7.109 |
| Market capitalisation | $220.1 billion |
TTM: trailing 12 months
There are currently 6.1 million Eli Lilly and Company shares held short by investors – that's known as the "short interest". This figure is 9.2% down from 6.8 million last month.
There are a few different ways that this level of interest in shorting Eli Lilly and Company shares can be evaluated.
Eli Lilly and Company's "short interest ratio" (SIR) is the quantity of Eli Lilly and Company shares currently shorted divided by the average quantity of Eli Lilly and Company shares traded daily (recently around 2.5 million). Eli Lilly and Company's SIR currently stands at 2.49. In other words for every 100,000 Eli Lilly and Company shares traded daily on the market, roughly 2490 shares are currently held short.
However Eli Lilly and Company's short interest can also be evaluated against the total number of Eli Lilly and Company shares, or, against the total number of tradable Eli Lilly and Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eli Lilly and Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Eli Lilly and Company shares in existence, roughly 10 shares are currently held short) or 0.0072% of the tradable shares (for every 100,000 tradable Eli Lilly and Company shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eli Lilly and Company.
Find out more about how you can short Eli Lilly and Company stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
Eli Lilly and Company's total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Dividend yield: 1.38% of stock value
Forward annual dividend yield: 1.47% of stock value
Dividend payout ratio: 40.97% of net profits
Eli Lilly and Company has recently paid out dividends equivalent to 1.38% of its share value annually.
Eli Lilly and Company has paid out, on average, around 40.97% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.47% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.18 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2021 (the "ex-dividend date").
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $127.0495 up to $275.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.2495. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Subscribe to trending stock alerts for a chance to win
Ever wondered how to buy shares in IronNet? We explain how and compare a range of providers that can give you access to many brands, including IronNet.
Ever wondered how to buy shares in Rocket Lab USA? We explain how and compare a range of providers that can give you access to many brands, including Rocket Lab USA.
Ever wondered how to buy shares in Camber Energy? We explain how and compare a range of providers that can give you access to many brands, including Camber Energy.
Ever wondered how to buy shares in Aterian? We explain how and compare a range of providers that can give you access to many brands, including Aterian.
Ever wondered how to buy shares in eFFECTOR Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including eFFECTOR Therapeutics.
Ever wondered how to buy shares in Santhera Pharmaceuticals Holding AG? We explain how and compare a range of providers that can give you access to many brands, including Santhera Pharmaceuticals Holding AG.
Ever wondered how to buy shares in Basilea Pharmaceutica? We explain how and compare a range of providers that can give you access to many brands, including Basilea Pharmaceutica.
Ever wondered how to buy shares in AB Science S.A.? We explain how and compare a range of providers that can give you access to many brands, including AB Science.
Ever wondered how to buy shares in Acacia Pharma Group? We explain how and compare a range of providers that can give you access to many brands, including Acacia Pharma Group.
Ever wondered how to buy shares in Blue Water Acquisition? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Acquisition.
